ES2145774T3 - Derivados de adenosina que tienen actividad agonista en a2. - Google Patents

Derivados de adenosina que tienen actividad agonista en a2.

Info

Publication number
ES2145774T3
ES2145774T3 ES93911492T ES93911492T ES2145774T3 ES 2145774 T3 ES2145774 T3 ES 2145774T3 ES 93911492 T ES93911492 T ES 93911492T ES 93911492 T ES93911492 T ES 93911492T ES 2145774 T3 ES2145774 T3 ES 2145774T3
Authority
ES
Spain
Prior art keywords
agonist activity
adenosine derivatives
adenosine
derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911492T
Other languages
English (en)
Inventor
Gloria Cristalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2145774T3 publication Critical patent/ES2145774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

DERIVADOS DE LA ADENOSINA QUE TIENEN UNA ACTIVIDAD AGONISTA A2 DE FORMULA (I), UN PROCESO PARA LA PREPARACION DE LOS MISMOS Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. LOS COMPUESTOS DE LA INVENCION SON UTILES PARA EL TRATAMIENTO DE PATOLOGIAS CARDIOVASCULARES Y DE ENFERMEDADES DEL SISTEMA NERVIOSO.
ES93911492T 1992-04-24 1993-04-21 Derivados de adenosina que tienen actividad agonista en a2. Expired - Lifetime ES2145774T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920973A IT1254915B (it) 1992-04-24 1992-04-24 Derivati di adenosina ad attivita' a2 agonista

Publications (1)

Publication Number Publication Date
ES2145774T3 true ES2145774T3 (es) 2000-07-16

Family

ID=11363039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911492T Expired - Lifetime ES2145774T3 (es) 1992-04-24 1993-04-21 Derivados de adenosina que tienen actividad agonista en a2.

Country Status (9)

Country Link
US (1) US5593975A (es)
EP (1) EP0637315B1 (es)
JP (1) JPH07508718A (es)
AT (1) ATE193299T1 (es)
CA (1) CA2134067A1 (es)
DE (1) DE69328722T2 (es)
ES (1) ES2145774T3 (es)
IT (1) IT1254915B (es)
WO (1) WO1993022328A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
ES2215609T3 (es) * 1999-02-01 2004-10-16 University Of Virginia Patent Foundation Composiciones para el tratamiento de la respuesta inflamatoria.
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
WO2002020539A1 (en) * 2000-09-08 2002-03-14 Toa Eiyo Ltd. Adenosine derivatives and use thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1351681B1 (en) * 2001-01-16 2010-09-15 Vascular Therapies, LLC Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
DE602004018808D1 (de) * 2003-10-31 2009-02-12 Cv Therapeutics Inc Antagonisten des a2b-adenosinrezeptors
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7655636B2 (en) * 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011513493A (ja) 2008-03-10 2011-04-28 コーネル ユニバーシティー 血液脳関門透過性の調節方法
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
US8263762B2 (en) 2009-06-30 2012-09-11 Dogwood Pharmaceuticals, Inc. Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
IN2015DN00538A (es) 2012-08-01 2015-06-26 Lewis And Clark Pharmaceuticals Inc
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
EP0267878A1 (en) * 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents

Also Published As

Publication number Publication date
WO1993022328A1 (en) 1993-11-11
JPH07508718A (ja) 1995-09-28
ITMI920973A0 (it) 1992-04-24
CA2134067A1 (en) 1993-11-11
US5593975A (en) 1997-01-14
ATE193299T1 (de) 2000-06-15
DE69328722D1 (de) 2000-06-29
IT1254915B (it) 1995-10-11
EP0637315B1 (en) 2000-05-24
EP0637315A1 (en) 1995-02-08
DE69328722T2 (de) 2000-12-14
ITMI920973A1 (it) 1993-10-24

Similar Documents

Publication Publication Date Title
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2084944T3 (es) Amidas terapeuticas.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ES2097341T3 (es) Indoles sustituidos como farmacos para el tratamiento del sida.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ECSP941122A (es) Derivados de 5-arilindoles
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
NO933524L (no) Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
IT8123940A0 (it) Derivati della s-adenosilmetionina, processo per la loro preparazione e composizioni terapeutiche che licontengono come principio attivo.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637315

Country of ref document: ES